The pharmacogGENEtics in Youth Depression (GENE-YD) study for personalizing antidepressant pharmacotherapy for young Western Australians – A feasibility study
Clinical meaningful improvements were observed, with the PGx-Guided group showing greater reductions in depressive symptom severity, higher rates of treatment response and remission, and improved quality-of-life outcomes compared with TAU.